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Summary Infection with certain types of human papillomavirus (HPV) presents a high risk for the subsequent development of cervical
intraepithelial neoplasia (CIN) and cervical carcinoma. Immunological mechanisms are likely to play a role in control of cervical HPV lesions.
The HPV E2 protein has roles in virus replication and transcription, and loss of E2 functions may be associated with progression of cervical
neoplasia. Accordingly, it is of interest to monitor immune responses to the E2 protein, and previous studies have reported associations
between serological reactivity to E2 peptide antigens and cervical neoplasia. In order to investigate serological responses to native, full-length
E2 protein, we expressed HPV-16 E2 proteins with and without an N-terminal polyhistidine tag using the baculovirus system. Purified HPV-16
E2 protein was used to develop enzyme-linked immunosorbent assays to detect serological IgG and IgA responses in cervical neoplasia
patients and controls. We found that serum IgA levels against the E2 protein were elevated in CIN patients relative to normal control subjects
but were not elevated in cervical cancer patients. Moreover, there appeared to be a gradient of response within cervical neoplasia such that
the highest antibody levels were seen in lower grades of neoplasia up to CIN 2, whereas lower levels were observed in CIN 3 and still lower
levels in cervical carcinoma. These findings suggest that the IgA antiboay response to E2 may associate with stage and progression in
cervical neoplasia.
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Human papillomaviruses comprise a large group of DNA viruses
that exclusively infect epithelium. Certain types of HPV are
capable of infecting genital mucosal epithelium, which can result
in cervical intraepithelial neoplasia (CIN). CIN is classified by
histopathology into stages 1, 2 and 3, which are thought to repre-
sent progressively advanced precursor lesions of cervical carci-
noma (CaCx). HPV infection is a prerequisite for the genesis of
almost all CIN and cervical carcinomas (Munoz et al, 1992;
Schiffman et al, 1993). Most CIN contains detectable HPV DNA.
HPV-16, -18 and related types have been classed as 'high-risk'
genital HPV types because of their associations with high-grade
CIN and CaCx (reviewed in Walboomers et al, 1994).
Genital-type HPV genomes are approximately 8 kbp in length
and comprise six open reading frames (ORFs) encoding early
functions (E1-E7) and two late ORFs encoding the capsid
proteins. The E2 ORF encodes an approximately 45-kDa nuclear
phosphoprotein that binds to specific sequence elements within the
HPV long control region (LCR). Binding ofthe E2 protein to these
elements functions in regulation ofHPV transcription and replica-
tion. Binding of E2 to sites near the constitutive early promoter of
HPV-16 or-18 can negatively regulate expression ofthe two major
Received 7June 1996
Revised 9 October 1996
Accepted23 October 1996
Correspondence to: S N Stacey, Department of Molecular Biology,
Paterson Institute for Cancer Research, Christie Hospital NHS Trust,
Manchester M20 9BX, UK
oncoproteins, E6 and E7. Expression of the E2 protein is thought
to be disrupted frequently in CaCx because ofbreakage of the E2
ORF when the viral DNA integrates. Loss of E2 expression may
influence progression of cervical neoplasia through release from
repression ofE6 and E7 synthesis (reviewed in Turek; 1994).
Studies from immunosuppressed patients show that immuno-
logical mechanisms, as yet poorly defined, are involved in control
ofHPV infections (reviewed in Benton et al, 1992). It is ofinterest
to target immunological events that may be occurring during the
early stages of cevical neoplasia and to monitor how such
immunological responses vary with increasing severity of lesion.
The E2 protein is an attractive candidate in this respect for several
reasons: firstly, E2 is required for viral replication and therefore
the protein would be expected to be present in productive lesions;
secondly, E2 protein expression may be reduced in higher stages
of neoplasia because of integration events and a differentiation
dependence of E2 RNA transcription (see Turek, 1994). There-
fore, it might be expected that immunological responses to the E2
protein could arise during premalignant cervical neoplasia and the
responses might vary from stage to stage.
It is widely anticipated that naturally protective immunity to
HPV is mediated through the cellular arm ofthe immune response
(Davies, 1994; Stanley et al, 1994). However, to date, no cellular
immune correlates ofprogression in cervical neoplasia have been
described. Serum antibody responses to HPV proteins can be
detected in some circumstances, using peptide or recombinant
antigens (reviewed in Galloway, 1994; Gissman and Muller,
1994). Previous studies using a peptide from the HPV-16 E2
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region as antigen reported IgA seropositivity in CIN patients,
whereas seropositive normal controls were significantly lower in
frequency (Dillner et al, 1989; Reeves et al, 1990). Subsequently,
it was found that an IgA response against this peptide was preva-
lent in cervical carcinoma (Lehtinen et al, 1992a; Dillner et al,
1994), although this has not been a universal finding (Mann et al,
1990). Investigators using E. coli-derived fusion proteins have not
detected E2 IgA responses in significant frequencies among
cervical cancer populations (Kochel et al, 1991; J Dillner et al,
1995). IgG responses to E2 peptides and E. coli fusion proteins
have been reported in association with CIN andcervical carcinoma
(J Dillner et al, 1995; L Dillner et al, 1995).
It has been shown previously that in the case of the E6 anti-
bodies, proteins produced using eukaryotic systems are necessary
to detect high frequencies of serological response (Stacey et al,
1992; Viscidi et al, 1993; Nindl et al, 1994). We therefore chose to
investigate the antibody response to E2 in a population repre-
senting a range of cervical neoplasia stages using the baculovirus
expression system to provide E2 antigen. The baculovirus system
was chosen because of its potential to provide large amounts of
antigen which would allow the development of high-capacity
ELISA assays based on a native form ofthe E2 protein. We report
here on the expression, characterization and purification of HPV-
16 E2 using baculovirus, the development of serological ELISAs
and the finding that the IgA response to E2 varies dramatically
with different stages ofcervical neoplasia.
MATERIALS AND METHODS
Construction of recombinant baculoviruses
The HPV-16 E2 open reading frame (coordinates 2756-3851;
Seedorf et al, 1985) was amplified by polymerase chain reaction
(PCR) from a genomic clone of HPV-16 (provided by H zur
Hausen) using Vent DNA polymerase (New England Biolabs)
according to the manufacturer's instructions. Primers were
CGGATCCAACGATGGAGACTCTTT (forward) and CGGTAC-
CGTGGATGCAGTATCAAG (reverse). The E2 start codon is
shown in bold. The amplified fragment was digested with BamHI
and KpnI and cloned into pBluescriptll (SK) (Stratagene). The
insert was sequenced using an ABI 373 automated DNA sequencer
(Applied Biosystems) and no coding changes were found. The
insert was recovered as a BamHI-KpnI fragment and cloned into
pVL941 and pBlueBacHisB (Invitrogen) to produce pVL-E2 and
pBBH-E2 respectively.
Routine baculovirus methods were taken from King and Possee
(1992). E2 plasmids were cotransfected into Sf9 cells with Baculo-
Gold (Pharmingen), and recombinant baculoviruses were isolated
initially by a single round ofplaque purification. Fourindependent
clones of each recombinant virus were screened for expression of
E2 protein by Coomassie staining and Western blotting using
lysates from small-scale cultures of HiS cells. A single clone of
each recombinant virus was selected, plaque-purified three more
times, expanded, titrated and then retested for expression before
use in further experiments. These clones were designated bVL-E2
and bBBH-E2, corresponding to the insertion-vector plasmid
designations described above. Preliminary experiments showed
that peak E2 expression in Hi5 cells occurred at 48 h after infec-
tion (data not shown), and this timing was used in all subsequent
experiments.
E2 reagent antisera
Rabbit polyclonal anti-HPV-16 E2 N-terminal and C-terminal
sera, raised against E. coli fusion proteins, have been described
previously (Sanders et al, 1995).
Western blotting
Approximately 5 x 105 cells were infected with 10 pfu per cell of
E2-baculovirus and lysed in 2 x PAGE sample buffer before frac-
tionation by 10% PAGE. Proteins were transferred to nitrocellu-
lose using a Bio-Rad Mini Trans-Blot apparatus. Membranes were
blocked overnight at 4°C in 5% Marvel-phosphate-buffered saline
(PBS). Specific antisera were added in 1:100 dilutions in blocking
buffer. Following incubation for 2 h at room temperature, the
membranes were washed with 0.2% Tween 20 in Tris-buffered
saline (TBS). Alkaline phosphatase-conjugated secondary anti-
bodies were added at a dilution of 1:500 in blocking buffer.
Secondary antibodies were rabbit anti-human-IgG (Dako D336),
rabbit anti-human-IgA (Dako D338) or swine anti-rabbit-Ig (Dako
D306). Following incubation for 2 h membranes were washed and
developed using Sigma-Fast BCIP/NBT alkaline phosphate
substrate (Sigma) for IgG or Pierce SuperSignal substrate for IgA.
Purification of His-tagged HPV-16 E2
Approximately 3 x 108 Hi5 cells were infected with bBBH-E2 and
harvested at 48 h after infection. A nuclearpellet was prepared and
resuspended in 25 ml of column binding buffer (20 mM sodium
phosphate, 1 M sodium chloride, pH 7.8). Nuclei were then soni-
cated with five bursts of 10 s at medium power using a DAWE-
7532B sonicator (Ultrasonics). Soluble nuclear material was
cleared by centrifugation at 15 000 g for 45 min at 4°C before
loading onto a 5-ml, Zn2+-charged Hi-Trap Chelating affinity
column (Pharmacia Biotech). The column was washed with 25 ml
of column binding buffer followed by 25 ml of column wash
buffer (20 mm sodium phosphate, IM sodium chloride, pH 6.3).
Bound proteins were eluted using a step gradient comprising
20 ml each of 5 mm, 10 mM, 15 mM, 20 mM, 50 mM, 100 mM
and 200 mm imidazole in column wash buffer. The presence,
purity and identity ofE2 protein in the fractions was monitored by
silver staining and reaction with reagent antisera. Yields of puri-
fied E2 protein ranged from 0.6-2.0 mg 1-1 ofHiS culture (approx-
imately 109 cells).
Selection of sera
Forty-five serum samples were collected from patients with histo-
logically diagnosed cervical carcinoma (43 squamous cell carci-
noma, two adenosquamous cell carcinoma) before radiotherapy
treatment at the Christie Hospital, Manchester, UK. The age range
ofthis population was 23-74 years with a mean of 45.7 years and
median 47 years. Of these patients, three were diagnosed with
stage IA carcinoma, 13 with IB, nine with IIA, six with IIB, one
with IIIA, 10 with IIIB and two with IV, one patient being referred
with a non-identified stage.
From the same hospital, 27 sera from patients with other forms
of cancer were collected before treatment and designated 'non-
genital cancer sera' (NGCa). The age range ofthis population was
34-72 years with a mean 54.4 years and median 53 years. The
cases comprised nine breast cancer, five ovarian cancer, three
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Figure 1 Expression of HPV 16-E2 proteins by recombinant baculoviruses.
(A) Coomassie blue-stained PAGE gels of Hi5 cells infected with HPV-16 E2
baculovirus bBBH-E2. Cells infected with HPV-16 E6 baculovirus bE6s were
used as a control. (B) Western blots using extracts from His-tagged HPV-16
E2 baculovirus bBBH-E2 (left) or native HPV-16 E2 baculovirus bVLE2 (right)
were developed using an anti-C-terminal HPV-16 E2 antiserum. Control
extracts were from uninfected Hi5 cells and from HPV-16 E6 baculovirus-
infected cells (bE6s). (C) Western blots using extracts as in B were
developed using an anti-N-terminal HPV-16 E2 antiserum
Borderline cytology indicates patients who had had an abnormal
smear, but no CIN was detected by histology. This group of
patients was selected specifically to contain examples of the
various stages of CIN. Material for HPV DNA typing was not
available from these patients.
Fifty-one serum samples were obtained from healthy women
working for the National Health Service who were sampled for
hepatitis B vaccination follow-up (the 'NHS' group). The age
range was 21-70 years with a mean of 46.6 years and median 46
years. This population was selected on the basis of age to match
the cervical carcinoma and non-genital cancer groups.
Fifty-five sera were obtained from children hospitalized with no
immunosuppressive or known HPV-associated diseases. The age
range of the population was 3-12 years. Individual patient details
were not examined further. Sera were collected under approval
from the Ethics Committee of the South Manchester Health
Authority and St Mary's Hospital for Women and Children.
Samples were stored at-200C.
ELISA
Ninety-six-well Immulon-4 ELISA plates (Dynatech Labora-
tories) were coated overnight at 4°C with 100 ,l per well ofpuri-
fied E2 antigen or solubilized nuclearextract, diluted in eitherPBS
or sodium carbonate/bicarbonate buffer (pH 9.6). Plates were then
washed with 0.1% Tween 20 in TBS. Non-specific binding sites
were blocked with 200 ,l of 2% bovine serum albumin (BSA),
0.1% Tween 20 in TBS for 2 h at 370C. After washing, sera were
diluted in blocking buffer and 100 gl per well added to the plate,
followed by further incubation for 2 h at 37°C. After washing,
alkaline phosphatase-conjugated rabbit anti-human IgG (Dako
D336) or IgA (Dako D338) were diluted 1:500 in blocking solu-
tion and 100 gl per well added and plates incubated for 1 h at
370C. After washing, plates were developed using Sigma 104
substrate in 10% diethanolamine (pH 9.6). Colour reactions were
quantitated at A405nm using an automated microplate reader
(Molecular Devices, UK). Readings were typically taken at 15, 30
and 60 min incubation. Positive and negative reference sera were
included on every plate. Reference sera were predefined using
western blotting to screen a subset ofsera from the NHS, COL and
CaCx groups. The ELISA value for the positive reference serum
was corrected to a value of 1.000 and a corresponding correction
factor applied to all absorbance values on the plate. Sera were
tested at 1:10, 1:100 and 1:1000 dilutions to ensure that readings
were taken in a rising phase of the titration curve. ELISA values
from the 1:10 dilutions only were used for statistical analysis.
non-small-cell lung carcinoma, five mesothelioma, two small-cell
lung carcinoma, one leiomyosarcoma, one non-Hodgkin's B-cell
lymphoma and one pancreatic carcinoma. This group comprised
eight men and 19 women.
The 'COL' population comprised sera from 72 patients
attending a colposcopy clinic at St Mary's Hospital, Manchester,
UK for investigation ofabnormal smearresults. The age range was
19-61 years with a mean of 29.9 years and median 28. Biopsies
were taken at the time of serum sampling. Histological diagnosis
was undertaken by the Pathology Department of St Mary's
Hospital, according to published criteria (Buckley et al, 1982). The
histological diagnosis was used to classify the 'COL' population
into 18 borderline cytology, eight CIN 1, 20 CIN 2 and 26 CIN 3.
Data analysis
The Mann-Whitney U-test was used to compare ELISA values
from different groups without assignment of a predetermined cut-
off. Cut-off values were subsequently assigned using the method
described in Muller et al (1992) using the mean ofthe NHS group
ELISA values plus two standard deviations as the cut-off. Chi-
squared analysis was used to compare seropositive and seronega-
tive frequencies between groups. To examine age effects each
group was first tested for an association between ELISA value and
age using linearregression analysis. Age-matched (±2 years) pairs
were then made between groups and differences in ELISA values
were tested for significance using the Wilcoxon test. No correc-
tions were applied for multiple comparisons.
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Figure 2 (A) Purification of the bBBH-BE2-derived E2 protein. E2 protein
from nuclear fractions of bBBH-E2-infected cells was purfied using Zn2+-
charged chelating affinity chromatography, followed by elution with an
imidazole step gradient. Eluted fractions were analysed by PAGE and silver
staining. Lane 1, molecular weight markers; lane 2, total nuclear extract; lane
3, column flow-through; lane 4, wash with column binding buffer; lane 5,
wash with column wash buffer; lane 6, elution with 10 mM imidazole; lane 7,
elution with 50 mm imidazole; lane 8, elution with 100 mm imidazole; lane 9,
elution with 200 mm imidazole; lane 10, elution with EDTA. Positions of
molecular weight markers (kDa) are shown. Band corresponding to the E2
protein is arrowed. (B) Reaction of human reference sera with purified HPV-
16 E2 protein in Western blots: left, IgA-positive reference; centre, IgA-
negative reference; right, IgG-positive reference
RESULTS
Expression of HPV-16 E2 proteins by recombinant
baculovirus
The E2 open reading frame was amplified by PCR and recombi-
nant baculoviruses generated using standard techniques. Two
baculovirus recombinants were made, one (bBBH-E2) containing
an N-terminal polyhistidine tag for purification, the other (bVL-
E2) containing the unfused E2 ORF. Infection ofinsect cells with
the baculovirus recombinants resulted in the appearance of novel
approximately 45 kDa bands visible by Coomassie blue staining
(Figure IA), that were not present in cells infected with a control
baculovirus bE6short (Stacey et al, 1994).
The identity of the HPV-16 E2 proteins was confirmed using
antibodies specific against the C- or N-terminal domains ofthe E2
protein. With the C-terminal serum, both bBBH-E2 and bVL-E2
revealed a single band of approximately 45 kDa (Figure IB),
corresponding to the novel band visible in Coomassie gels. The N-
terminal antiserum also detected an approximately 30 kDa frag-
ment, which appeared to be a breakdown product (Figure 1C).
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Figure 3 Reaction of lgG-positive sera with HPV-16 and HPV-11 E2
proteins. Cells infected with bVL-E2 or HPV-11 E2 baculovirus were used in
Western blots with human sera. Sera from three patients with cervical
carcinoma (CaCx 1, 2 and 3) showed a strong positive lgG response. None
of the sera gave a positive response to the HPV-11 E2 in this assay. Anti-N-
Ig G + terminal antiserum (aN) was used as a control
This suggested that the N-terminal domain of HPV-16 E2 might
comprise a proteolytically resistant domain, whereas the C-
terminal domain is protease sensitive. Subcellular localization
studies using immunofluorescence and cell fractionation showed
that the N-terminal fragments were restricted to the cytoplasm,
whereas the nucleus contained exclusively full-length E2 protein
(data not shown).
Purification of HPV-16 E2 protein and ELISA
development
The HPV-16 E2 protein expressed in the bBBH-E2 vector
contained six consecutive histidine residues in the N-terminal to
allowpurification bymetal chelating affinitychromatography. The
full-length E2 protein was purified from nuclei, eluting as a single
45-kDa band in 50-200 mM imidazole fractions (Figure 2A).
For the development of ELISAs, positive and negative human
reference sera for IgG and IgA were defined using Western blot-
ting against purified E2 antigen (Figure 2B). Preliminary ELISAs
using positive and negative reference sera showed that IgG and
IgA reactivities to the purified antigen were equivalent to reactivi-
ties to unpurified, untagged antigen present in nuclear extracts
frombVL-E2 infected cells. A concentration of250 ng per well of
purified E2 protein was selected by chequerboard titration ELISA
as being non-antigen-limiting conditions with several different
dilutions ofpositive reference sera up to 1:10. This concentration
ofantigen was used in all subsequent experiments.
Serological responses to E2 protein
Sera from 45 cervical carcinoma patients (CaCx), 27 non-genital
cancer patients (NGCa) and 72 colposcopy patients (COL) were
tested in E2 ELISA for IgG and IgA reactivity. In addition, sera
from 51 normal women working for the National Health Service
were taken from employment-related hepatitis-B screening
(NHS). Sera from 55 children hospitalized with no known HPV-
associated or immunosuppressive conditions were tested for E2
IgA antibodies only.
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Table 1 Differences in E2 IgA ELISA reactivities between patient groups
Mann-Whitney Wilcoxon signed- X2-testc
U-testa rank testb
COLvsNHS <0.0002 0.0001 0.0002
COL vs CaCx < 0.0002 0.001 <0.0001
COL vs NGCa < 0.0002 (H) 0.0028d
CIN vs NHS < 0.0002 0.0022 0.0019
NHS vs CaCx 0.001 0.01 NS
COL vs children < 0.0002 (-) 0.0001
CIN 3 vs (BL to CIN 2) 0.0022 NS 0.0069d
CIN 3 vs CIN 1+2 0.0094 NS 0.0168d
NHS vs (BL and CIN 1) < 0.0002 0.0007 0.0003
aP-values based on continuous ranking of ELISA values. bP-values based on
age-matched pairs with continuous ranking of ELISA values. cP-values based
on a cut-off level for seropositivity defined as the mean of the NHS control
samples plus two standard deviations after elimination of outliers (Muller et
al, 1992). dFisher's exact test was used for small samples. COL, colposcopy
group; CIN, cervical intraepithelial neoplasia; NHS, control group of National
Health Service women; CaCx, cervical carcinoma; NGCa, non-genital cancer,
BL, borderline cytology; NS, not significant; (-), not tested.
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No significant differences between the groups were seen for IgG
seroreactivity using the ELISA (not shown). This finding was
confirmed using Western blotting; cells were infected with bVL-
E2 and lysates used for Western blotting. Seventy human sera were
retested, comprising 37 cervical carcinoma sera, 16 CIN, eight
borderline cytology and nine normal donors. The anti-E2 rabbit
sera were used as positive controls. As shown in Figure 3, three
cervical carcinoma sera gave strong positive IgG responses to
HPV-16 E2 but not against a baculovirus-derived HPV- 11 E2
control (LRZ unpublished results). Comparison with control blots
using the anti-N-terminal serum showed that the sera of these
carcinoma patients reacted specifically with E2 protein bands. In
IgG ELISA, these three strongly reacting sera also gave high OD
values (>0.900), but the frequency of this response in the CaCx
population was very low (3 out of 45). We conclude that most of
the patients and controls were negative for E2 IgG.
For IgA, ELISA values in the COL group were significantly
higher than those in either the NHS group, the CaCx group, the
NGCa group or the children (Table 1). These differences were not
attributable to age differences between the population; patients and
controls were age matched 1:1 andretested. Significant differences
were seen between age-matched COL and CaCx or NHS controls
(Table 1 and Figure 4A). Too few age-matched pairs could be
produced using the NGCa vs COL patients for reliable testing. We
concluded that ELISA values for E2 IgA are significantly elevated
in COL patients and that the values drop between COL and CaCx.
A similar finding was also made when only patients with histo-
logically confirmed CIN were considered (Table 1).
Values for the CaCx group were not increased relative to normal
controls, indeed ELISA values were significantly lower than those
ofthe NHS control group in some tests (Mann-Whitney U-test and
Wilcoxon test). ELISA values were used to calculate a cut-off
value for IgA seropositivity based on the mean ofthe NHS control
group plus two standard deviations using the method described in
Muller et al (1992). As shown in Figure 4B, the highest frequency
of seropositivity was found in the COL group (53%) compared
with the NHS control group (18%). The frequency of seroposi-
tivity in the CaCx group was much lower (8.8%). The frequency in
the non-genital cancer group was 19%, similar to the NHS control,
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Figure 4 IgA serological reactivity to the HPV-16 E2 protein using ELISA.
(A) Boxplot showing corrected ELISA absorbance values for children, COL
group, age-matched controls for the COL group, cervical carcinoma (CaCx)
group and age-matched controls for the cervical carcinoma group. The
boxplot shows median, 25th and 75th percentiles (limits of boxes), 10th and
90th percentiles (bars). Points outside this range are plotted individually.
(B) Comparison of the IgA seropositivity between the NHS control group,
colposcopy group (COL), cervical carcinoma (CaCx), non-genital cancer
(NGCa) and children groups. (C) Stratification of the IgA anti-E2 positive CIN
population. The CIN group was divided into borderline cytology (BL), CIN
1+2 and CIN 3
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and 11% in the children. The frequency of seropositivity in COL
was found to be significantly different from NHS controls, NGCa,
children and CaCx. Also, seropositivity was significantly more
frequent in patients with histologically confirmed CIN than NHS
controls. In summary, we concluded that the COL patients had a
significantly elevated frequency of IgA seropositivity to E2, rela-
tive to both normal controls and cervical carcinoma patients.
The COL group was stratified by stage into three groups based
on histopathological classifications: BL (borderline cytology),
CIN 1+2 and CIN 3 (Figure 4C). Within the COL group, the CIN 3
subgroup was found to have significantly lower ELISA values
than the other two subgroups combined (BL to CIN 2) or when
compared with the CINI+2 group alone (Table 1). Using the cut-
off values described above, it was found that CIN 3 patients had a
significantly different incidence of seropositivity (31%) than the
other two COL subgroups combined (66%) or when compared
alone with CIN1+2 (64%). This suggested that the decrease in
seropositivity that had been observed for CaCx relative to CIN
was also reflected in a decrease in CIN 3 seropositivity relative to
the other grades ofCIN.
It was also of interest to determine whether differences were
apparent between normal controls and the early stages ofCIN. As
shown in Table 1, ELISA values and seropositivity rates were
significantly elevated in BL and CIN 1 compared with NHS
controls. Again, this effect was found not to be due to differences
in age between the two groups. We concluded that the increases in
serum E2 IgA may already be apparent in early stages of cervical
dysplasia
The E2 IgA ELISA values did not vary with age in each group,
except for the NHS control group in which a significant trend for
increase with age was observed (P < 0.01). Using the cut-off
values described above, all except one ofthe seropositive subjects
in the NHS control group were over 50 years of age. For women
under 50 years old in the COL and NHS control groups, the speci-
ficity of a seropositive response for COL was over 95%, with a
sensitivity of 57%. A 32.9-fold relative risk (95% confidence
interval 4.2-254.3) was estimated for COL related to seroposi-
tivity for women under 50.
DISCUSSION
Previous reports have shown that patients with CIN tended to have
detectable serum IgA antibodies against an HPV 16 E2 peptide
(Dillner et al, 1989; Reeves et al, 1990). Subsequent reports have
shown that anti-E2 peptide IgA responses were significantly asso-
ciated with cervical carcinoma (Lehtinen et al, 1992a; Dillner et
al, 1994), although other investigators have not found this (Mann
et al, 1990). E2 IgA responses have been reported to decline after
surgical resection of tumours (Lehtinen et al, 1992b; Lenner et al,
1995). These kinetics would suggest that an IgA response against
E2 is short lived. Viewed in this light, the reported occurrence of
IgA responses to the E2 protein in cervical carcinoma (Lehtinen et
al, 1992a; Dillner et al, 1994; L. Dillner et al, 1995) is somewhat
puzzling as loss of E2 expression is supposed to be a progression
factor in cervical neoplasia, and IgA responses would not be
expected to be long-lasting in the absence ofantigenic stimulation.
Integration into chromosomal DNA occurs in an estimated 70% of
tumours and this event usually disrupts E2 expression. However, a
substantial proportion of tumours contains either episomal plus
integrated or episomal only HPV sequences (Fuchs et al, 1989;
Matsukura et al, 1989; Cullen et al, 1991). Investigations of E2
protein expression by CaCx and CIN lesions are clearly warranted,
as are further studies ofthe longevity ofE2 IgA responses.
The patterns of E2 IgA seroreactivity observed in the present
study follow more closely the expected distributions ofE2 protein
expression in CIN and CaCx. We observed increasing levels ofE2
IgA in early grades ofCIN which appeared to then decline in more
severe lesions to a point at which levels were lower than normal in
cervical cancer patients. These findings may reflect reduced levels
of E2 expression in advanced CIN lesions (perhaps because of
restricted viral replication) and CaCx (perhaps because of integra-
tion and loss of activity of E2-specific promoters). It is not clear
why the baculovirus E2-based assays described here and the previ-
ously described antipeptide assays differ in the detection ofE2 IgA
and IgG responses in cervical carcinoma patients. The spectrum of
HPV types detected by the two assays might differ, and the rela-
tionship between HPV DNA type and seroreactivity has yet to be
clarified for both types of assay. The two types of assay may also
detect different antibody specificities. It is notable that we were
unable to detect E2 IgG responses in a pool of CaCx sera previ-
ously proven seropositive in an E2-245 peptide-based assay (LRZ
and J Dillner, unpublished observations). The 245 epitope is
contained within the DNA binding domain of the E2 protein and
may be masked or non-antigenic when the protein is in its native
conformation (Gautier et al, 1991). However, we did find a low
frequency (6.6%) of CaCx sera that reacted strongly in both IgG
ELISA and Western blot assays. As it is clear that we were able to
detect seropositives in this group, it remains possible that popula-
tion differences can account for the apparent differences between
the peptide ELISAs and the present assays.
The findings of this paper are based on a cross-sectional study
and accordingly do notprovide information as to the kinetics ofthe
E2 IgA response. This means that it is not clear whether within an
individual patient antibodies would tend to rise with the advent of
CIN and then fall again as the lesion progressed, eventually to
disappear with the genesis of a cervical carcinoma. An alternative
interpretation is that antibody levels appear to drop with progres-
sion because those women who fail to make an appropriate immune
response at an early stage of neoplasia are more likely to progress
to higher stages. In this way, the lower levels ofantibody in CIN 3
and CaCx could be seen as being due to the selection ofindividuals
who have failed to mount an adequate immune response to the
virus. This issue can be settled only by prospective studies. In either
case, monitoring of E2 IgA levels may provide valuable progres-
sion markers in cervical neoplasia and might expose underlying
immunological phenomena related to progression.
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